💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Susoctocog Alfa

CHEMBL5315075 Phase 4 Aprobado Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Susoctocog alfa is a recombinant porcine factor VIII (B-domain deleted) used for the treatment of acute bleeding episodes in adults with acquired hemophilia A, a rare autoimmune disorder in which patients develop inhibitory antibodies against endogenous factor VIII. The porcine origin of susoctocog alfa provides functional coagulation activity in patients whose antibodies have lower cross-reactivity to porcine versus human factor VIII. It restores normal hemostasis in patients unresponsive to human factor VIII replacement due to high-titer inhibitors.

Mecanismo de acción

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Susoctocog alfa is a recombinant porcine factor VIII (B-domain deleted) used for the treatment of acute bleeding episodes in adults with acquired hemophilia A, a rare autoimmune disorder in which patients develop inhibitory antibodies against endogenous factor VIII. The porcine origin of susoctocog alfa provides functional coagulation activity in patients whose antibodies have lower cross-reactivity to porcine versus human factor VIII. It restores normal hemostasis in patients unresponsive to human factor VIII replacement due to high-titer inhibitors.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Susoctocog Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315075. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.